SecBot SecBot
8-K ·Filed Apr 7, 2026

SLNO

SOLENO THERAPEUTICS INC
BEARISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001193125-26-144511
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Traders should view this as a near-term setback for SLNO, eliminating expected 2026 regulatory approval and commercialization in Europe. Monitor for future updates on re-engagement with EMA, but expect downward pressure on the stock due to lost market potential.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$52.35
T+0 close · Apr 7, 2026 · via day close
Latest settled
+1.05%
T+20 · $52.90
Vs SPY
−8.73%
α at T+20
Next horizon
T+60
due 5mo ago
  1. T+0 · Apr 7 $52.35entry
  2. T+1 · 7mo ago +0.48%α −2.06% · $52.60
  3. T+5 · 7mo ago +0.52%α −4.81% · $52.62
  4. T+20 · 7mo ago +1.05%α −8.73% · $52.90
  5. T+60 · due 5mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Soleno Therapeutics has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT (VYKATTM XR) in Europe for Prader-Willi syndrome, citing business and strategic considerations. The decision preserves the option to re-engage with regulators in the future, but removes near-term commercial prospects in Europe.

Key Facts

  • Soleno Therapeutics withdrew its MAA for VIOKAT (diazoxide choline) in Europe for Prader-Willi syndrome (PWS).
  • The application was under review by the European Medicines Agency (EMA) with a decision expected in mid-2026.
  • The withdrawal was voluntary and based on 'business and strategic considerations'.
  • The company retains the ability to re-engage with regulators in the future if a viable pathway emerges.

Financial Impact

Removes potential European revenue from VIOKAT in 2026; delays or eliminates a key growth driver for the company.

revenuemarket expansionregulatory milestones

Risk Factors

  • Loss of European market opportunity for VIOKAT delays revenue diversification.
  • Strategic uncertainty raises questions about management's commitment to international expansion.
  • Potential perception of regulatory or commercial challenges underlying the withdrawal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-144511
Document: 0001193125-26-144511-index-headers.html0001193125-26-144511
Document: 0001193125-26-144511-index.html0001193125-26-144511
Document: 0001193125-26-144511.txt0001193125-26-144511

Track record

10 reports on SLNO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
  2. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
  3. May 28, 202624w ago 15-12G Bearish 8/10 No price data
  4. May 28, 202624w ago EFFECT Bearish 5/10 No price data
  5. May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Entry $53.01 No price data
  6. Apr 7, 202631w ago 8-K Bearish 7/10 Viewing Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
  7. Apr 6, 202632w ago 8-K Bullish 8/10 Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
  8. Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
  10. Feb 26, 202637w ago 8-K Neutral 3/10 Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 7h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026